Clinical Trials Logo

Neuromuscular Monitoring clinical trials

View clinical trials related to Neuromuscular Monitoring.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06238219 Recruiting - Clinical trials for Neuromuscular Monitoring

Management of Neuromuscular Blocking Agents and Their Antagonism

NMBA_periop
Start date: April 17, 2024
Phase:
Study type: Observational

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023. Research hypothesis: Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.

NCT ID: NCT03605225 Recruiting - Clinical trials for Neuromuscular Blockade

Development and Validation of an Android-based Application for Anaesthesia Neuromuscular Monitoring

Start date: February 7, 2018
Phase: N/A
Study type: Interventional

The present study aims to assess the accuracy of a newly developed Android Smartphone Application in measuring the degree of Neuromuscular block in the perioperative period. This will be achieved by comparing Train-of-four Ratio measurements using this application with those obtained from a standard commercialized neuromuscular monitor.

NCT ID: NCT02880787 Recruiting - Clinical trials for Neuromuscular Monitoring

Comparison of Two Neuromuscular Transmission Monitors Based on Acceleromyography: TOF-Watch SX® and TOFScan®

TOFScan
Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose is to evaluate the reproducibility of neuromuscular monitoring data of recovery from neuromuscular blockade, obtained with TOFScan® and TOF-Watch SX®, in adult and pediatric population. Secondary purposes are to evaluate the reproducibility of data obtained with 2 monitors for: - the onset of clinical action of curare: suppression of the first response of train of four monitoring (T1) of 95% initial value - the duration of clinical action of curare: recovery of the first response of train of four monitoring (T1) to 25% initial value - recovery of first (T1), second (T2), third (T3) and fourth response (T4) of train of four monitoring, and recovery of T4/T1 to 40% and 60% initial value (T4/T1 0.4 and 0.6) - complete recovery from curarisation, at T4/T1=90% and T4/T1=100%.